ArticleBMC cancer2025
Azelaic acid attenuates CCL2/CCR2 axis-mediated skin trafficking of acute myeloid leukemia cells through NF-κB/MAPK signaling modulation in keratinocytes.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Temporal Transcriptomic Mapping Reveals Angiogenesis and Immune Remodeling During Fat Grafting.Aesthetic plastic surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe involvement of CCL2/CCR2 in leukemic cell infiltration into the skin, specifically in leukemia cutis (LC), remains largely unexplored. Oxidative stress has been demonstrated to induce the upregulation of CCL2 expression, while the antioxidant properties of azelaic acid (AZA) have been proven to exert anti-acute myeloid leukemia (AML) effects.
aimsTo investigate the role of CCL2/CCR2 in the pathogenesis of leukemia cutis, and to evaluate whether azelaic acid (AZA) can inhibit the infiltration of leukemic cells into the skin and its possible mechanism.
methodsThe migratory capacity of leukemic cells toward skin tissue was evaluated in vitro to determine the effects of CCL2/CCR2 and its modulation by AZA treatment. Concurrently, the regulatory effects of AZA on the NF-κB/MAPK signaling pathway in keratinocytes were investigated. In vivo studies were conducted using a patient-derived xenograft (PDX) AML mouse model, wherein AZA was administered via tail vein injection. A quantitative assessment of leukemic cell infiltration in skin tissues was performed to compare the therapeutic efficacy of AZA treatment versus untreated controls.
resultsAZA treatment significantly reduced CCL2 secretion in keratinocytes and decreased CCR2 expression in AML cells, consequently attenuating the migratory capacity of AML cells toward keratinocytes. Mechanistically, AZA downregulated the NF-κB/MAPK signaling pathway in keratinocytes. In vivo studies using the PDX-AML mouse model demonstrated that AZA administration markedly reduced leukemic cell infiltration in skin tissues compared to untreated controls.
conclusionsCCL2/CCR2 plays an important role in the pathogenesis of LC. AZA effectively inhibits leukemic cell infiltration into the skin by downregulating CCL2 production through negative regulation of the NF-κB/MAPK signaling pathway in keratinocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.